Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
Background. Erenumab was the first preventive medication targeted to the pathogenesis of migraine to reach Lithuanian market. Previously, evidence of the safety and efficacy of erenumab was supported only by clinical study results, but more recently, real-life data started to appear. The aim of thi...
Saved in:
Main Authors: | Austėja Dapkutė, K. Ryliškienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2021-12-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27594 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01) -
New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor
by: K. Ryliškienė, et al.
Published: (2019-12-01) -
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
by: Hans-Christoph Diener, et al.
Published: (2025-02-01) -
Differentially localizing isoforms of the migraine component calcitonin gene-related peptide (CGRP), in the mouse trigeminal ganglion: βCGRP is translated but, unlike αCGRP, not sorted into axons
by: Sofia Lyng Wæver, et al.
Published: (2025-01-01) -
Epidemiology of clinically significant migraine in Israel: a retrospective database study
by: A. Shifrin, et al.
Published: (2025-02-01)